Presented by Gemini for Zia H Shah MD

Audio teaser: How sarcoidosis mimics failing dental implants

Introduction and Epidemiological Framework

Sarcoidosis is a multisystem, sterile, non-necrotizing granulomatous disorder of uncertain etiology that represents one of the most complex clinical enigmas in modern immunology and internal medicine. Initially described in 1877, the disease is defined by a highly heterogeneous clinical course, ranging from asymptomatic, spontaneously remitting localized inflammation to progressive, fibrotic organ failure leading to severe morbidity and mortality. While the lungs and thoracic lymph nodes are the primary sites of involvement—present in over 90% of cases and forming the basis of the classic Scadding staging system—sarcoidosis is a systemic disease capable of infiltrating virtually any organ system. Extrapulmonary manifestations frequently involve the skin, heart, central nervous system, and the orofacial region, presenting significant diagnostic challenges due to overlapping clinical features with other granulomatous, neoplastic, and autoimmune conditions.

The global epidemiology of sarcoidosis demonstrates profound geographic, ethnic, and demographic variability. Worldwide incidence rates span from 1 to 160 cases per 100,000 individuals, heavily influenced by regional diagnostic practices and genetic population structures. The highest prevalence is consistently observed in Scandinavian countries, where the annual incidence ranges from 11 to 23 cases per 100,000. In the United States, systemic sarcoidosis exhibits a prevalence of 35.2 cases per 100,000 population, with distinct clustering along the East Coast and in urban centers. African American populations bear a disproportionate burden of the disease, exhibiting an incidence three times higher than that of Caucasian populations and a propensity for more severe, chronic, and treatment-refractory clinical phenotypes. Conversely, the disease is exceedingly rare in parts of Asia, with incidence rates falling below 1 case per 100,000. A bimodal age distribution is frequently noted, with incidence peaks occurring between 25 to 35 years and 45 to 65 years of age, alongside a marked female predominance regardless of geographic or racial boundaries.

The overall five-year mortality rate for sarcoidosis is approximately 7%. The leading causes of sarcoidosis-related death are advanced cardiopulmonary complications. Specifically, up to 40% of patients with pulmonary sarcoidosis progress to Stage IV fibrocystic disease, characterized by lung parenchyma fibroplasia, bronchiectasis with hilar retraction, and an up to 70% risk of developing precapillary pulmonary hypertension. Stage IV disease with greater than 20% fibrosis on high-resolution computed tomography carries a 5-year mortality risk exceeding 40%. Additionally, cardiac sarcoidosis, which may present with life-threatening ventricular arrhythmias, complete heart block, or sudden cardiac death, is responsible for a significant proportion of mortality, accounting for up to 80% of sarcoidosis-related deaths in certain regions such as Japan.

Despite advances in recognizing systemic manifestations, extrapulmonary presentations in the head and neck—particularly salivary gland and lingual sarcoidosis—frequently elude early diagnosis. These orofacial lesions may serve as the initial, isolated harbinger of systemic disease. Consequently, understanding the nuanced pathophysiology, clinical presentation, and diagnostic framework for these specific sites is critical for early detection, comprehensive organ assessment, and the implementation of emerging targeted immunomodulatory therapies.

Etiopathogenesis and Molecular Mechanisms

The precise etiologic agent of sarcoidosis remains elusive; however, contemporary consensus posits that the disease arises from a complex, multifactorial interplay between genetic susceptibility, environmental exposures, and profound immunological dysregulation. It is widely theorized that the disease is initiated by an aberrant, exaggerated cell-mediated immune response to one or more poorly degraded antigens, which persist within macrophages and trigger a chronic granulomatous cascade.

Genetic Susceptibility and HLA Allelic Associations

Genetic predisposition plays a fundamental role in disease expression, severity, and specific organ tropism. Familial clustering is well-documented, with first-degree relatives of affected patients exhibiting a 3.7-fold increased risk of developing the disorder. Furthermore, studies involving twins have demonstrated a significantly higher concordance rate in monozygotic twins compared to dizygotic twins, affirming a strong heritable component.

Human Leukocyte Antigen (HLA) class II alleles are the primary genetic determinants in sarcoidosis. These alleles confer either susceptibility or protection, often dictating the distinct clinical phenotype an individual will manifest. Specific alleles, including HLA-DRB103, DRB111, DRB112, DRB114, and DRB115, are established risk factors for disease susceptibility across various populations. In contrast, HLA-DRB101 and DRB1*04 exert protective effects against generalized sarcoidosis in Caucasian populations.

Fascinatingly, specific HLA haplotypes correlate with highly distinct clinical syndromes. The acute, self-limiting phenotype known as Löfgren’s syndrome—characterized by bilateral hilar lymphadenopathy, erythema nodosum, and arthritis—is strongly associated with the HLA-B8/DR3 haplotype. Furthermore, while HLA-DRB104 is generally protective against broad systemic disease, its presence is paradoxically enriched in patients presenting with Heerfordt’s syndrome and isolated ocular sarcoidosis. In one cohort, 55% of patients with Heerfordt’s syndrome-associated symptoms possessed the HLA-DRB104 allele, compared to only 26.6% of the general sarcoidosis population, indicating that organ-specific tropism, particularly involving the eyes and salivary glands, is deeply rooted in local immunogenetic programming. In African American populations, HLA-DQB1 alleles appear to exert a more significant role in disease susceptibility than HLA-DRB1 alleles, a genetic divergence that may partially explain the racial disparities observed in disease chronicity and severity.

Environmental and Occupational Triggers

Recent meta-analyses and pathophysiological studies have linked several environmental and occupational toxic particles to the onset of pulmonary and systemic sarcoidosis. A comprehensive evaluation of occupational hazards identified distinct categories of toxic particles associated with an increased risk of developing the disease: inorganic dusts, organic dusts, chemicals, and mixed fumes. Prolonged occupational exposure to crystalline silica, pesticides, and organic molds or mildew significantly increases the odds of developing pulmonary sarcoidosis. Furthermore, exposure to the complex mixture of particulate matter in World Trade Center (WTC) dust has been definitively associated with an elevated incidence of granulomatous lung disease. These particulates are hypothesized to serve as persistent niduses for granuloma formation when phagocytosed by alveolar macrophages that lack the enzymatic machinery to degrade them effectively. Interestingly, certain metallic exposures, such as occupational exposure to gold, have been identified in sensitivity analyses as potential protective factors, though the exact immunochemical mechanism for this inverse relationship remains to be fully elucidated.

Infectious Agents as Putative Antigens

Infectious agents remain the most intensely studied putative antigenic triggers. Mycobacterium tuberculosis complex and Cutibacterium acnes (formerly Propionibacterium acnes) are the leading candidates. The detection of mycobacterial DNA markers, such as the IS6110 gene (a highly specific marker for M. tuberculosis), and mycolic acid cell wall components within sarcoid granulomas suggests that sarcoidosis may represent an aberrant, prolonged immune clearance mechanism following an initial, perhaps subclinical, mycobacterial infection. These antigens elicit a T-helper type 1 (Th1) immune response, identical to the pathway driving classical infectious granulomatosis. Similarly, the frequent identification of C. acnes DNA, particularly within pulmonary and lymph node tissues, supports the hypothesis that persistent intracellular microbial elements drive chronic inflammation in genetically susceptible hosts. Other implicated microorganisms include Borrelia burgdorferi, Chlamydia pneumoniae, Leptospira species, and various herpesviruses and retroviruses, suggesting that sarcoidosis may be a uniform immunologic reaction pattern to a diverse array of microbial insults.

The Immune Paradox and Intracellular Signaling Pathways

A defining and perplexing pathophysiological hallmark of sarcoidosis is the “immune paradox”—a state of intense, localized granulomatous inflammation occurring simultaneously with profound peripheral immune anergy. Clinically, this anergy is manifested as a depressed delayed-type hypersensitivity reaction, such as cutaneous unresponsiveness to tuberculin skin tests and common recall antigens.

This paradox is orchestrated by a spatial and functional disequilibrium between effector T cells and regulatory T (Treg) cells. Antigen stimulation in genetically predisposed individuals enhances the phagocytic activity of antigen-presenting cells, namely macrophages and dendritic cells, which subsequently fail to clear the inciting antigen. Upon antigen presentation, there is a massive clonal expansion and recruitment of CD4+ Th1 and Th17 cells to the site of inflammation. These effector cells secrete extraordinary quantities of pro-inflammatory cytokines, specifically interleukin-2 (IL-2), interferon-gamma (IFN-γ), and tumor necrosis factor-alpha (TNF-α). These cytokines critically modulate the aggregation, continuous activation, and ultimate fusion of macrophages to form the highly structured epithelioid granuloma.

Concurrently, there is an accumulation of CD4+CD25brightFoxP3+ regulatory T cells at the periphery of the granuloma and within the peripheral blood. While these Treg cells exert strong anti-proliferative effects on naïve T cells peripherally—thereby causing the observed clinical anergy—they exhibit a diminished capacity to suppress TNF-α production at the disease site, allowing granuloma formation to proceed unchecked. Over time, chronic disease may also lead to an accumulation of immunosuppressive CD8+ T cells in the peripheral circulation, further reinforcing the anergic state.

Recent translational research has decoded specific aberrant intracellular signaling pathways that sustain this relentless inflammation. Mechanistic target of rapamycin (mTOR)-driven metabolic shifts in macrophages are crucial for their prolonged survival, differentiation into epithelioid cells, and eventual fusion. Furthermore, hyperactivation of the Janus kinase/signal transducers and activators of transcription (JAK-STAT) signaling pathway has been heavily implicated in the pathogenesis of cutaneous, multiorgan, and refractory sarcoidosis. The precise identification of JAK-STAT and mTOR dysregulation has opened entirely novel avenues for targeted biological therapies, marking a critical paradigm shift away from broad, non-specific immunosuppression.

Histopathology of the Sarcoid Granuloma

The absolute histopathological gold standard for diagnosing sarcoidosis, irrespective of the organ system involved, is the identification of well-formed, “tight,” non-caseating (non-necrotizing) epithelioid granulomas. Unlike the caseating granulomas classically seen in active tuberculosis or dimorphic fungal infections, sarcoid granulomas typically maintain cellular integrity without central caseous necrosis. However, it must be noted that small amounts of focal fibrinoid necrosis can occasionally be observed within sarcoid granulomas; the presence of such micro-necrosis does not preclude the diagnosis, provided all other clinical and pathological features align.

The microarchitecture of the sarcoid granuloma is highly organized and consistent. The central core consists of tightly clustered epithelioid histiocytes (macrophages that have undergone secretory transformation) and multinucleated giant cells, which may be of the Langhans or foreign-body type. Interspersed within this central macrophage core are CD4+ T helper lymphocytes, which maintain the inflammatory drive. This active central core is surrounded by a concentric, fibrotic rim populated primarily by CD8+ T lymphocytes, B lymphocytes, regulatory T cells, and fibroblasts. In lymph nodes and other heavily involved tissues, the usual architectural framework is effaced by these discrete granulomas, which frequently coalesce into larger, nodular structures.

A fascinating and unique diagnostic feature of sarcoid tissue is the frequent presence of distinct cytoplasmic inclusion bodies within the multinucleated giant cells or the extracellular matrix. While none of these inclusions are strictly pathognomonic for sarcoidosis, they are highly characteristic, and their identification offers significant utility when evaluating complex tissue biopsies, such as those from the salivary glands or oral mucosa.

Salivary Gland Sarcoidosis: Presentation and Diagnostic Imperatives

Salivary gland involvement is a relatively rare but clinically vital manifestation of sarcoidosis, occurring in fewer than 6% to 10% of all diagnosed patients. Despite its statistical rarity, the presentation of salivary sarcoidosis holds profound clinical importance. According to comprehensive systematic reviews, in approximately 82.1% of cases where the salivary glands are involved, the glandular swelling serves as the very first clinical sign of systemic disease. Thus, the presentation of a salivary mass frequently prompts the initial diagnostic workup that uncovers occult pulmonary, thoracic, or cardiac involvement, shifting the patient’s trajectory toward necessary systemic monitoring.

Clinical Characteristics and Functional Impact

The parotid gland is the undisputed epicenter of major salivary gland sarcoidosis, implicated in over 80% (up to 82.1%) of reported salivary cases. The most frequent presentation is bilateral, firm, and painless enlargement (parotidomegaly) that develops insidiously over weeks to months. While the parotid is preferred, submandibular and sublingual major glands, as well as minor salivary glands distributed ubiquitously throughout the oral mucosa, can also be synchronously infiltrated.

The dense infiltration of functional salivary acini by non-caseating granulomas, coupled with subsequent fibrosis, leads to architectural effacement and a marked decline in exocrine secretory function. Consequently, xerostomia (dry mouth) is the most frequent functional symptom. This lack of saliva severely impacts oral health and function, leading to secondary complications such as persistent difficulty chewing, dysphagia, dysarthria, and an elevated risk for rampant dental caries or opportunistic oral candidiasis. In a small minority of cases (up to 6%), the glandular swelling may present as acutely painful; this atypical pain is usually attributed to rapid capsular distension, localized inflammatory flare, secondary bacterial sialadenitis, or localized compression of the facial nerve.

Imaging of the affected salivary glands provides non-specific but supportive data. Magnetic resonance imaging (MRI) typically reveals homogeneous glandular enlargement with increased signal intensity on T2-weighted sequences and avid asymmetric or symmetric contrast enhancement. Nuclear medicine imaging, such as Gallium-67 citrate scintigraphy or 18F-FDG PET, may demonstrate the classic “panda sign”—defined as bilateral, pathological radiotracer uptake in the parotid and lacrimal glands coupled with physiological tracer accumulation in the nasopharynx.

The Diagnostic Utility of Minor Salivary Gland Biopsy

Given that sarcoidosis involvement of the salivary glands can be clinically silent or only minimally symptomatic, minor salivary gland biopsy (specifically, labial salivary gland biopsy) has emerged as an exceptionally high-yield, minimally invasive diagnostic tool. The minor salivary glands frequently harbor occult non-caseating granulomas even in the absence of gross parotidomegaly.

This procedure is particularly valuable in the diagnostic workup of suspected ocular sarcoidosis or neurosarcoidosis, where obtaining direct tissue from the eye, optic nerve, or central nervous system is associated with unacceptable surgical morbidity. In patients presenting with unexplained chronic uveitis, optic neuritis, or cranial neuropathies, a labial minor salivary gland biopsy demonstrating non-caseating granulomas is often sufficient to definitively diagnose systemic sarcoidosis when integrated with compatible clinical symptoms and elevated inflammatory markers.

Differential Diagnostic Pitfalls

The clinical presentation of bilateral parotid swelling accompanied by xerostomia necessitates a rigorous and methodical differential diagnosis, as salivary sarcoidosis can easily be misdiagnosed as other prominent autoimmune or infiltrative conditions. The primary clinical confounders are Primary Sjögren’s Syndrome (SS) and IgG4-Related Disease (IgG4-RD), both of which present with identical chief complaints of sicca symptoms and glandular enlargement.

Furthermore, infectious etiologies such as cervicofacial actinomycosis (a chronic suppurative bacterial infection presenting as an indurated mass at the angle of the jaw) and gastrointestinal conditions like Crohn’s disease (which can present identically as orofacial granulomatosis) must be carefully excluded, as their respective therapeutic algorithms differ radically from the immunosuppressive protocols required for sarcoidosis.

Heerfordt’s Syndrome: The Uveoparotid Fever Phenotype

A highly specific, fascinating, and historically significant manifestation of combined salivary and ocular sarcoidosis is Heerfordt’s Syndrome. Originally described by Christian Heerfordt in 1909 as “febris uveo-parotidea subchronica,” the syndrome was later definitively linked to the underlying pathology of sarcoidosis by Waldenström in 1937.

Clinical Presentation and Incidence

Heerfordt’s syndrome is classically defined by a rigorous clinical tetrad:

1. Parotid Gland Enlargement (Parotitis): Usually bilateral, firm, and painless, caused by extensive granulomatous infiltration of the glandular parenchyma.
2. Uveitis: Typically presenting as a bilateral, granulomatous anterior uveitis (iritis or iridocyclitis). Patients report severe photophobia, blurred vision, excessive tearing, and conjunctival hyperemia. Uveitis is the most common ocular manifestation of general sarcoidosis, affecting up to 30% of all patients, and is the driving inflammatory event in this syndrome.
3. Facial Nerve Palsy: Occurring in 25–50% of patients with this syndrome, the unilateral or bilateral lower motor neuron facial paralysis is secondary to direct mechanical compression by the massively enlarged parotid tissue, or, more insidiously, due to direct epineural and perineural granulomatous infiltration of the seventh cranial nerve.
4. Low-Grade Fever: A prominent constitutional symptom reflecting the acute, systemic inflammatory nature of this specific phenotype.

The “complete” form of Heerfordt’s syndrome—where all four diagnostic criteria are met simultaneously—is exceptionally rare, documented in only about 0.3% of the total sarcoidosis population. In a large cohort of 1,000 sarcoidosis patients, only three individuals exhibited the complete syndrome. An “incomplete” form, defined by the presence of at least two of the primary symptoms (e.g., parotitis and facial palsy, or uveitis and parotitis), is slightly more common, occurring in approximately 1.3% of cases.

Genetic Links and Clinical Prognosis

Recent extensive immunogenetic profiling has revealed that patients presenting with symptoms of Heerfordt’s syndrome have a remarkably high positivity rate for the HLA-DRB104 allele. In a definitive cohort study, 55% of patients exhibiting symptoms associated with Heerfordt’s syndrome carried the HLA-DRB104 allele, compared to 35.9% in healthy controls, and only 26.6% of the broader, generalized sarcoidosis population. Notably, 60% of patients with isolated parotid and salivary gland enlargement without ocular engagement were also HLA-DRB1*04 positive. This powerful genetic linkage indicates that the simultaneous occurrence of uveitis, parotitis, and neuropathy is not coincidental, but rather a specific, genetically predetermined inflammatory cascade.

Prognostically, Heerfordt’s syndrome is generally considered a subacute variant with a favorable evolutionary profile compared to fibrotic pulmonary disease. It is typically self-limiting, with most patients achieving full clinical remission within 12 to 36 months when appropriately and swiftly managed with systemic corticosteroids. However, failure to rapidly initiate corticosteroid therapy (usually prednisone at doses of 20 to 40 mg/day, sometimes escalating to 80 mg/day) can result in permanent, irreversible lower motor neuron facial paralysis. Furthermore, uncontrolled ocular inflammation can lead to severe visual impairment due to cystoid macular edema, which occurs in up to 10% of patients with sarcoid uveitis.

Lingual and Oral Sarcoidosis: Bone versus Soft Tissue Disease

While the salivary glands represent the most frequent orofacial manifestation, direct granulomatous involvement of the oral cavity and the tongue is exceedingly rare. An exhaustive systematic review analyzing case reports and series from 1943 to 2024 identified only 77 documented patients with true oral sarcoidosis across 59 studies. Mirroring systemic sarcoidosis, oral involvement shows a distinct female predominance (ranging from 61.5% in bone-involved cases to 72.5% in soft tissue cases, with an overall female-to-male ratio of approximately 2.2:1 to 2.67:1). The mean age of presentation is 43.3 years, falling squarely within the classical fifth-decade incidence peak.

Oral sarcoidosis is pathophysiologically and clinically bifurcated into two distinct entities, presenting entirely different diagnostic challenges: non-bone-involved (soft tissue) and bone-involved (intraosseous) sarcoidosis.

Lingual and Soft Tissue Sarcoidosis

Non-bone-involved oral sarcoidosis typically targets the buccal mucosa, gingiva, hard palate, and the tongue. Symptoms in these soft tissues are often insidious, asymptomatic, and easily misdiagnosed as benign hyperplasias or localized trauma.

• Lingual Presentation: Sarcoidosis of the tongue usually manifests as painless, non-ulcerated, grayish-white or red-violet papules, plaques, or submucosal nodules. A critical diagnostic feature is that these lesions show a marked predilection for the tip and dorsal surfaces of the tongue. This location provides a crucial clinical distinction from oral squamous cell carcinoma, which typically favors the high-risk zones of the lateral borders and ventral surfaces.
• Gingival and Palatal Presentation: Patients may present with generalized, asymptomatic gingival hyperplasia, localized eruptive edema, or a well-circumscribed, red-violet nodular mass on the midline of the hard palate.

While lingual and soft tissue lesions are generally painless, they can cause minor discomfort during mastication and phonation. Importantly, the tongue serves as a sentinel for innate immune surveillance. Massive granulomatous infiltration can disrupt the microscopic architecture of taste buds and their regenerative niches, leading to early alterations in taste perception—an underappreciated and understudied neurological corollary of lingual sarcoidosis that severely impacts quality of life.

Intraosseous Oral Sarcoidosis and Implant Mimicry

Bone-involved sarcoidosis within the oral cavity is a highly destructive, resorptive process that predominantly affects the mandible (followed closely by the maxilla). The chronic granulomatous inflammation within the marrow spaces causes rapid, aggressive alveolar bone loss. Clinically, this presents as localized jaw pain, severe gingival recession, and the marked, sudden mobility of previously healthy teeth (noted in 34.6% of intraosseous cases).

A critical contemporary diagnostic pitfall in modern dentistry is the presentation of mandibular sarcoidosis mimicking peri-implantitis or severe, aggressive periodontitis. In middle-aged and older adults receiving dental implants, the sudden, unexplained, and rapid resorption of alveolar bone around the titanium implant hardware is easily and routinely mistakenly attributed to bacterial biofilm infection or biomechanical occlusal failure. However, a failure to respond to conventional surgical debridement and antibiotic therapy should immediately raise the clinical index of suspicion for intraosseous sarcoidosis, particularly in patients with no history of radiation therapy or osteoclast inhibitory therapy (bisphosphonates).

Because oral lesions constitute the very first manifestation of sarcoidosis in roughly half (53.8%) of these patients, dental professionals, periodontists, and oral and maxillofacial surgeons play a critical frontline diagnostic role. Persistent mucosal nodules, atypical lingual plaques, or unexplained rapid alveolar bone loss must prompt a diagnostic tissue biopsy and subsequent systemic evaluation for occult pulmonary, cardiac, or neurosarcoidosis.

Modern Diagnostics and the Evolving Biomarker Landscape

Because sarcoidosis is rigorously defined as a diagnosis of exclusion—reliant on compatible clinical and radiological findings, histological evidence of non-caseating granulomas, and the definitive ruling out of alternative infectious or autoimmune causes—the identification of reliable, non-invasive diagnostic and prognostic biomarkers remains a high priority.

Serological Biomarkers: The Shift from ACE to sIL-2R

1. Serum Angiotensin-Converting Enzyme (ACE): For decades, serum ACE has been the traditional biochemical marker for sarcoidosis, predicated on the fact that the enzyme is actively secreted by epithelioid cells and macrophages within the active granuloma. However, its clinical utility is severely limited. The sensitivity of serum ACE for diagnosing sarcoidosis is notoriously low, ranging between 41% and 78%, and it lacks definitive specificity, as it can be elevated in a wide variety of other granulomatous, infectious, and fibrotic pulmonary conditions. Furthermore, ACE levels do not consistently correlate with disease severity, pulmonary function improvement, or therapeutic response.
2. Soluble Interleukin-2 Receptor (sIL-2R): Current immunological research heavily favors sIL-2R as a vastly superior marker of real-time disease activity. sIL-2R directly reflects the level of pathogenic T-cell activation occurring at the active periphery of the forming granulomas. Extensive studies demonstrate that sIL-2R levels are markedly elevated in untreated sarcoidosis. In a comparative cohort, median sIL-2R levels in clinically active sarcoidosis were exceptionally high at 6,050 pg/ml, compared to 4,667 pg/ml in IgG4-Related Disease, and 1,515 pg/ml in healthy control populations. Rising sIL-2R levels can reliably precede clinical relapses, making it an invaluable tool for monitoring longitudinal response to immunosuppressive therapy and differentiating active, reversible inflammatory phases from irreversible established fibrosis.

Advanced Imaging and Organ Probability Assessment

While conventional radiography (such as chest X-rays used for establishing Scadding stages I through IV) remains foundational, advanced imaging modalities are now mandatory to map the full extent of extrapulmonary disease.

• 18F-Fluorodeoxyglucose (18F-FDG) PET/CT: Essential for identifying metabolically active inflammatory lesions, distinguishing active, reversible granulomas from inert residual fibrosis, and locating occult sites for high-yield diagnostic biopsies in challenging cases. It is especially critical in diagnosing cardiac sarcoidosis. To utilize PET for cardiac evaluation, specialized prolonged fasting protocols are mandated to suppress physiological myocardial glucose uptake, thereby allowing the pathological 18F-FDG uptake of active granulomatous inflammation to be clearly visualized.
• Cardiac Magnetic Resonance (CMR) Imaging: The non-invasive modality of choice for detecting structural damage and myocardial infiltration in cardiac sarcoidosis. CMR reveals patchy late gadolinium enhancement (LGE), primarily in the septal wall and apical regions, indicative of myocardial scarring. The presence of LGE portends a significantly high risk for lethal ventricular arrhythmias and sudden cardiac death.

Diagnostic probability across all organ systems is now standardized using the World Association for Sarcoidosis and Other Granulomatous Disorders (WASOG) organ assessment instrument. This rigorous clinical tool categorizes presentations into highly probable, probable, or possible sarcoidosis, effectively guiding clinicians on exactly when high-risk invasive biopsies are scientifically and ethically justified.

Evolving Therapeutic Paradigms: 2025–2026 WASOG Updates

The therapeutic management of sarcoidosis is currently undergoing a rapid and profound paradigm shift. Historically, clinical decision-making was severely hampered by a sheer lack of randomized controlled trials, leading to a heavy, empirical reliance on chronic, high-dose systemic corticosteroid administration. However, long-term corticosteroid use is intrinsically associated with profound cumulative morbidity, including osteoporosis, refractory diabetes, hypertension, and opportunistic immunosuppression. The major universally accepted indications for initiating treatment remain the prevention of permanent end-organ dysfunction (especially critical in pulmonary, cardiac, ocular, and neurosarcoidosis) and the aggressive preservation of patient quality of life.

In 2024 and 2025, the WASOG task forces, in conjunction with the American Thoracic Society (ATS) and the European Respiratory Society (ERS), issued updated consensus statements and clinical trial endpoint guidelines. These updates strongly advocate a definitive move toward the earlier implementation of steroid-sparing therapies and the utilization of biomarker-driven individualized care regimens.

First-Line Therapy: Optimized and Minimized Corticosteroids

While oral glucocorticoids (e.g., prednisone) remain the absolute cornerstone of acute therapy for highly symptomatic or organ-threatening disease, historical dosing strategies have been completely overhauled. The recent pivotal SARCORT trial provided high-level evidence that low-dose prednisolone is clinically non-inferior to traditional, higher-dose regimens in managing symptomatic pulmonary sarcoidosis. Consequently, current WASOG and ATS/ERS guidelines strongly recommend initiating corticosteroids at the lowest effective dose (typically starting at 20 to 40 mg daily, abandoning historical 60-80 mg induction doses) and tapering as rapidly as clinical stability and serial sIL-2R levels allow.

Second-Line Therapy: Early Implementation of Steroid-Sparing Agents

To mitigate the inevitable toxicity of chronic steroids, disease-modifying antirheumatic drugs (DMARDs) are now routinely introduced much earlier in the disease course, often concurrently with the initial steroid taper.

• Methotrexate (MTX): The landmark PREDMETH clinical trial validated methotrexate as the most feasible, effective, and tolerable first-line steroid-sparing agent for both acute and chronic sarcoidosis, including complex neurosarcoidosis and pulmonary disease. It is widely used to facilitate successful, permanent steroid weaning without precipitating disease relapse.
• Alternative DMARDs: Azathioprine, leflunomide, and mycophenolate mofetil serve as robust alternative second-line options for patients intolerant to methotrexate or those with specific organ toxicities. Antimalarials, such as hydroxychloroquine and chloroquine, demonstrate particular efficacy for isolated cutaneous sarcoidosis, as well as symptomatic oral, lingual, and minor salivary gland lesions.

Third-Line and Biological Therapies

For patients with refractory disease, advanced fibrocystic lung changes, or life-threatening cardiac and neurological involvement, biologic therapies targeting specific cytokine pathways are heavily indicated.

• Anti-TNF Agents: Infliximab (a monoclonal antibody against TNF-α) possesses the most robust clinical data among biologics. It is highly efficacious in treating refractory pulmonary, cutaneous, and neurosarcoidosis, as well as the intractable uveitis associated with severe Heerfordt’s syndrome. However, careful monitoring is required; discontinuation of Infliximab after 6 to 12 months is associated with a staggering disease relapse rate of over 50%, necessitating long-term, indefinite maintenance therapy in severe clinical phenotypes.

Emerging Targeted Therapeutics (The 2025-2026 Landscape)

Recent advances in decoding the intricate molecular pathophysiology of the sarcoid granuloma have yielded a new generation of targeted immunomodulators that precisely inhibit the specific intracellular pathways driving macrophage fusion and persistent T-cell activation.

• JAK-STAT Inhibitors: Tofacitinib, an oral Janus kinase inhibitor, has demonstrated remarkable, rapid efficacy in salvage therapy for chronic, multiorgan, and refractory cutaneous sarcoidosis. By directly inhibiting the downstream intracellular signaling of multiple pro-inflammatory cytokines simultaneously, tofacitinib effectively dismantles the granulomatous architecture at the cellular level where traditional therapies fail.
• IL-6 Pathway Inhibition: Interleukin-6 and its downstream product, serum amyloid A (SAA), are potent promoters of Th1-mediated granulomatous inflammation. Tocilizumab, an anti-IL-6 receptor monoclonal antibody, is currently being investigated as a powerful steroid-sparing biologic in chronic sarcoidosis, showing early, significant promise in disrupting chronic granuloma persistence.
• Efzofitimod: This is a novel, highly targeted immunomodulator that binds specifically to neuropilin-2 (NRP2). It selectively downregulates the hyperactive inflammatory state of alveolar macrophages. Recent pivotal trials have highlighted its unprecedented ability to produce profound steroid-sparing effects while simultaneously preserving or improving lung function, marking it as a highly promising future anchor therapy for pulmonary sarcoidosis.

Defining Clinical Trial Endpoints

The rapid proliferation of these novel therapeutic agents necessitated a rigorous standardization of how therapeutic success is measured. The 2024-2025 WASOG Clinical Trial Endpoint Task Force established that traditional, isolated physiological markers—such as forced vital capacity (FVC) or diffusing capacity for carbon monoxide (DLCO)—fluctuate spontaneously by as much as 2% even in placebo arms, and entirely fail to capture the holistic, multisystem impact of the disease.

Current consensus mandates the use of highly structured composite endpoints (specifically the SARCOUT core outcome sets). These new endpoints strictly integrate objective pulmonary and cardiac physiology, defined steroid-reduction metrics, and critical patient-reported outcomes. Specifically, robust instruments that measure sarcoidosis-associated fatigue (SAF) and small-fiber neuropathy symptoms (such as the King’s Sarcoidosis Questionnaire and the Fatigue Assessment Scale) are now required, as these exact symptoms most heavily dictate and degrade the patient’s daily quality of life.

Conclusion

Sarcoidosis remains a highly complex, heterogeneous multisystem disorder whose etiology sits squarely at the nexus of genetic susceptibility, aberrant immunologic signaling, and varied environmental exposures. While the lung remains the primary organ of involvement, extrapulmonary manifestations—particularly those localized to the salivary glands and the oral cavity—are of profound diagnostic and prognostic significance. Salivary gland enlargement, whether occurring in isolation or as part of the classic Heerfordt’s syndrome tetrad, and the exceedingly rare but highly destructive presentation of lingual or intraosseous mandibular sarcoidosis, frequently represent the initial heralds of undiagnosed systemic disease. It is critical for clinicians, spanning internal medicine, ophthalmology, and maxillofacial surgery, to recognize these orofacial phenotypes and differentiate them meticulously from Sjogren’s syndrome, IgG4-related disease, and oral malignancies using advanced histopathology and biomarkers like sIL-2R.

The landscape of sarcoidosis management has shifted definitively and permanently from an era of empiric, high-dose corticosteroid dependence toward biomarker-driven precision immunology. With the integration of sIL-2R monitoring, advanced functional imaging with PET and CMR, and the advent of highly targeted therapies such as JAK-STAT inhibitors, Neuropilin-2 modulators, and specific cytokine blockades, the therapeutic focus is now firmly set on inducing early remission, minimizing treatment-related toxicity, and preserving long-term quality of life. As guided by the latest ATS/ERS/WASOG consensus initiatives, the continued unravelling of the molecular drivers of granulomatosis promises to further refine and individualize the standard of care for all manifestations of this relentless systemic disease.